[1]
|
D. M. Leod, J. Dowman, H. Hammond, T. Leete, K. Inoue and A. Abeliovich, “The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology,” Neuron, Vol. 52, No. 4, 2006, pp. 587-593.
|
[2]
|
A. S. Fauci, J. B. Martin, D. L. Braunwald, K. J. Kasper, S. L. Issabacher, E. Hauser, J. D. Wilson and D. L. Longo, “Harrison’s Principles of Internal Medicine,” 14th Edition, McGraw-Hill, New York, 1998, Vol. 2.
|
[3]
|
N. A. Boon, N. R. Colledge, B. R. Walker and J. A. A. Hunter, “Davidson’s Principles and Practice of Medicine,” 20th Edition, Elsevier, London, 2006.
|
[4]
|
A. A. Karadaghy, J. M. Lasak, J. S. Chomchai, K. M. Khan, J. Marian, M. J. Drescher and D. G. Drescher, “Quantitative Analysis of Dopamine Receptor Messages in the Mouse Cochlea,” Molecular Brain Research, Vol. 44, No. 1, 1997, pp. 151-156.
doi:10.1016/S0169-328X(96)00261-6
|
[5]
|
J. J. Hagan, D. N. Middlemiss, P. C. Sharpe and G. H. Poste, “Parkinson’s Disease: Prospects for Improved Drug Therapy,” Trends in Pharmacological Sciences, Vol. 18, No. 5, 1997, pp. 156-163.
|
[6]
|
M. B. Stern, “Contemporary Approaches to the Pharmacotherapeutic Management of Parkinson’s Disease: An Overview,” Neurology, Vol. 40, No. 1, 1997, pp. 2-9.
|
[7]
|
S. M. Verma, B. K. Razdan and D. Sasmal, “3D-QSAR Study of 8-azabicyclo[3.2.1] Octane Analogs Antagonists of Cholinergic Receptor,” Bioorganic Medicinal Chemistry Letters, Vol. 19, No. 11, 2009, pp. 3108-3112.
doi:10.1016/j.bmcl.2009.03.164
|
[8]
|
A. H. Blatt, “Organic Synthesis,” 2nd Edition, John Wiley & Sons, Inc., New York, Vol. 1, 1947.
|
[9]
|
P. R. Mc Guirk, M. R. Jefson, D. D. Mann, N. C. Elliott, P. Chang, E. P. Cisek, C. P. Cornell, T. D. Gootz, S. L. Haskell and M. S. Hindahl, “Synthesis and Structure-Activity Relationships of 7-Diazabicyclo Alkylquinolones, Including Danofloxacin, a New Quinolone Antibacterial Agent for Veterinary Medicine,” Journal of Medicinal Chemistry, Vol. 35, No. 4, 1992, pp 611-620.
|
[10]
|
P. Yogeeswari, D. Sriram, L. R. J. Suniljit, S. S. Kumar and J. P. Stables, “Anticonvulsant and Neurotoxicity Evaluation of Some 6-chlorobenzothiazolyl-2-thiosemicarbazones,” European Journal of Medicinal Chemistry, Vol. 37, No. 3, 2002, pp. 231-236.
doi:10.1016/S0223-5234(02)01338-7
|
[11]
|
B. K. Razdan, A. K. Sharma, K. Kumari, R. B. Bodla, B. L. Gupta and G. K. Patnaik, “Studies on Azabicyclo Systems: Synthesis and Spasmolytic Activity of Analogs of 9- methyl-3,9-diazabicyclo[4.2.1]nonane and 10-methyl-3, 10-diazabicyclo[4.3.1]decane,” European Journal of Medicinal Chemistry, Vol. 22, No. 6, 1987, pp. 573-577.
doi:10.1016/0223-5234(87)90299-6
|
[12]
|
C. Morpurgo, “Effect of Antiparkinson Drugs on a Phenothiazine Induced Catatonia Reaction,” Archives internationales de pharmacodynamie et de thérapie, Vol. 137, 1962, 84-90.
|
[13]
|
S. K. Kulkarni, A. Arzi and P. N. Kaul, “Modification of Drug-Induced Catalepsy and Tremors by Quizapine in Rats and Mice,” Journal of Pharmacology, Vol. 30, 1980, pp. 129-135.
|
[14]
|
S. K. Kulkarni, “Hand Book of Experimental Pharmacology,” Vallabh Prakashan, Delhi, 1999.
|
[15]
|
M. D. E. Nerland and E. E. Smissman, “Synthesis and Evaluation of Brain Catecholamine Depletion by N-alkyl Derivatives of 6-Aminodopamine,” Journal of Medicinal Chemistry, Vol. 19, No. 1, 1976, pp 163-164.
doi:10.1016/0003-2697(71)90426-X
|
[16]
|
T. Nagatsu, “Biochemistry of Catecholamines, the Biochemical Method,” University Park Press, Baltimore/ London/Tokyo, 1973.
|
[17]
|
A. I. Vogel, “Text Book of Quantitative Inorganic Analysis Including Elementary Instrumental Analysis,” 3rd Edition, ELBS and Longman, London, 1971.
|